Oncolytics reports positive preclinical data combining pelareorep with pan-RAS inhibitor in colorectal cancer model
ONCY•Dosing schedule remains a key variable
Benefits from pelareorep were less apparent when dosing shifted to a weekly schedule, pointing to dosing as a key development variable.
Work will expand across additional dosing schedules and RAS-driven models to assess whether the combination can deepen responses or delay resistance.
Preclinical results in RAS-driven colorectal cancer
Oncolytics Biotech announced positive preclinical results for pelareorep combined with a pan-RAS inhibitor in RAS-driven colorectal cancer.
Results were disclosed now; no future presentation was specified.
Combination treatment reduced tumor growth versus control, with pelareorep activity maintained alongside RAS inhibition and no antagonism observed.
